Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Teramura

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Thrombosis Research|February 15, 1984
Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrateT Matsuda, M Ogawara, R Miura, et al.
Research Communications in Molecular Pathology and Pharmacology|December 1, 1996
Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acidK Iwasaki, Y Miyazaki, Y Teramura, et al.
Journal of Virology|December 1, 1994
Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cellsT Shimizu, H Uenishi, Y Teramura, et al.
Nihon Geka Gakkai Zasshi|December 1, 1983
[Intraoperative dual-mode independent lung ventilation for open-chest surgery: conventional volume-set ventilation in healthy lung and high frequency jet ventilation in diseased lung]T Arai, T Harioka, C Miyake, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 29, 1999
The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjectsA Möller, K Iwasaki, A Kawamura, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1990
Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytesM Nakanishi, N Kan, T Okino, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1990
[Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy]N Kan, T Okino, K Satoh, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapyK Satoh, N Kan, T Okino, et al.
Cancer Research|October 1, 1990
Effect of heat treatment on tumor cells and antitumor effector cellsK Mise, N Kan, T Okino, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytomaN Kan, T Okino, M Nakanishi, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Thrombosis Research|February 15, 1984
Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrateT Matsuda, M Ogawara, R Miura, et al.
Research Communications in Molecular Pathology and Pharmacology|December 1, 1996
Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acidK Iwasaki, Y Miyazaki, Y Teramura, et al.
Journal of Virology|December 1, 1994
Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cellsT Shimizu, H Uenishi, Y Teramura, et al.
Nihon Geka Gakkai Zasshi|December 1, 1983
[Intraoperative dual-mode independent lung ventilation for open-chest surgery: conventional volume-set ventilation in healthy lung and high frequency jet ventilation in diseased lung]T Arai, T Harioka, C Miyake, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 29, 1999
The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjectsA Möller, K Iwasaki, A Kawamura, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1990
Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytesM Nakanishi, N Kan, T Okino, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1990
[Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy]N Kan, T Okino, K Satoh, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapyK Satoh, N Kan, T Okino, et al.
Cancer Research|October 1, 1990
Effect of heat treatment on tumor cells and antitumor effector cellsK Mise, N Kan, T Okino, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1989
Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytomaN Kan, T Okino, M Nakanishi, et al.
Pageof 3